India, Aug. 31 -- Alnylam Pharmaceuticals Inc. (ALNY) announced that new data from the HELIOS-B Phase 3 study, presented at the ESC Congress 2025, demonstrated the long-term cardiovascular benefit of AMVUTTRA (vutrisiran) in adults with cardiomyopathy due to wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
The data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population and a 42% r...